CytomX Therapeutics, Inc. CTMX
- Market cap
- $599.2M
- P/E
- 0.0×
Follow CTMX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.10 | 10.40 | 12.51 | 5.10 | 3.60 | 3.68 | 1.17 | 1.04 | 0.83 | 0.40 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 20.94 | 24.67 | 35.00 | 19.75 | 15.44 | 10.05 | 4.73 | 3.02 | 5.85 | 4.62 |
High Price
|
|||
| 80 | 93 | 139 | 160 | 146 | 178 | 118 | 122 | 121 | 69 |
Employees
|
|||
| 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 |
Revenue/Emp
|
|||
| 15 | 72 | 60 | 57 | 100 | 37 | 53 | 101 | 138 | 76 |
Revenue
|
|||
| 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
|
|||
| (59) | (44) | (70) | (103) | (47) | (116) | (99) | 3 | 32 | (17) |
EBT
|
|||
| (391.67%) | (60.89%) | (118.15%) | (178.58%) | (46.63%) | (310.54%) | (186.82%) | 3.28% | 23.24% | (22.48%) |
EBT Margin
|
|||
| (59) | (43) | (85) | (102) | (33) | (116) | (99) | (1) | 32 | (17) |
Net Income
|
|||
| 3 | 2 | 0 | 0 | 2 | 3 | 2 | (5) | (4) | (1) |
Depreciation
|
|||
| 0.42 | 1.93 | 1.43 | 1.27 | 2.17 | 0.58 | 0.81 | 1.37 | 1.64 | 0.55 |
Revenue/Sh
|
|||
| (1.63) | (1.16) | (2.03) | (2.26) | (0.71) | (1.81) | (1.51) | (0.01) | 0.38 | (0.15) |
Earnings/Sh
|
|||
| (0.06) | 4.58 | (1.81) | (3.10) | 0.11 | (1.86) | (1.69) | (0.76) | (1.02) | (0.55) |
Cash Flow/Sh
|
|||
| (0.06) | (0.04) | (0.09) | (0.08) | (0.05) | (0.03) | (0.03) | (0.01) | 0.00 | 0.00 |
Capex/Sh
|
|||
| (0.11) | 4.54 | (1.90) | (3.18) | 0.06 | (1.88) | (1.71) | (0.77) | (1.02) | (0.55) |
Free CF/Sh
|
|||
| 2.17 | 1.88 | 3.14 | 1.13 | 1.08 | (0.01) | (1.30) | (0.64) | (0.01) | 0.72 |
Book Value/Sh
|
|||
| 36 | 37 | 42 | 45 | 46 | 64 | 66 | 74 | 84 | 138 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.71 | 0.00 |
PE Ratio
|
|||
| 25.80 | 11.29 | 10.57 | 6.55 | 3.01 | 7.44 | 1.99 | 1.23 | 0.63 | 7.71 |
PS Ratio
|
|||
| 4.95 | 11.57 | 4.81 | 7.37 | 6.07 | 0.00 | 0.00 | 0.00 | 0.00 | 5.93 |
PB Ratio
|
|||
| 13.70 | 6.07 | 3.24 | 1.45 | (0.11) | (0.64) | (1.57) | (0.45) | (0.07) | 5.97 |
EV/Sales
|
|||
| (49.60) | 2.57 | (2.43) | (0.58) | (3.62) | 0.20 | 0.74 | 0.79 | 0.10 | (6.00) |
EV/FCF
|
|||
| (2) | 170 | (76) | (140) | 5 | (119) | (111) | (56) | (86) | (76) |
Op' Cash Flow
|
|||
| (2) | (2) | (4) | (3) | (2) | (2) | (2) | (1) | 0 | 0 |
Capex
|
|||
| (4) | 169 | (79) | (144) | 3 | (121) | (113) | (57) | (87) | (76) |
FCF
|
|||
| 152 | 327 | 348 | 218 | 223 | 232 | 84 | 27 | 22 | 97 |
Working Cap'
|
|||
| — | — | — | 3 | 3 | 4 | 4 | 5 | — | — |
Total Debt
|
|||
| (182) | (374) | (436) | (293) | (313) | (302) | (190) | (170) | (101) | (137) |
Net Debt
|
|||
| 78 | 70 | 131 | 51 | 50 | 0 | (86) | (47) | 0 | 99 |
Sh' Equity
|
|||
| (29.72%) | (14.44%) | (19.80%) | (25.61%) | (9.40%) | (33.20%) | (33.09%) | (0.25%) | 19.77% | (14.97%) |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| (57.59%) | (58.09%) | (84.28%) | (112.35%) | (65.17%) | (469.64%) | 230.41% | 0.85% | (133.06%) | (41.34%) |
ROE
|
|||
CytomX Therapeutics, Inc. (CTMX) key facts
- CytomX Therapeutics, Inc. (CTMX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- CytomX Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $76.2 million, down 44.8% from fiscal 2024.
- As of September 25, 2026, CTMX traded at $2.70, a market capitalization of $599.2 million.
- Return on equity was −41.3% and debt-to-equity 0.00.
CytomX Therapeutics, Inc. (CTMX) Latest News
27 Aug
CytomX Therapeutics secures FDA Fast Track Designation for Varsetatug masetecan (Varseta-M) in relapsed/refractory metastatic colorectal cancer. Fast Track designation accelerates regulatory review and potential approval for Varseta-M, strengthening CTMX position in oncology.
7 Aug
CytomX Therapeutics Inc (CTMX) Q2 2026 earnings call highlights show Varetta M advancing in development toward key milestones. Varetta M pipeline progress signals moderate effects on CTMX operations and positioning without guaranteed broad trajectory shifts.
6 Aug
CytomX Therapeutics Q2 earnings call highlighted financial results, pipeline updates, and operational progress for the period. Quarterly earnings calls typically provide moderate updates on finances and pipeline without fundamentally shifting long-term trajectory.
CytomX Therapeutics posted a Q2 loss and missed revenue estimates. Q2 loss and revenue shortfall signals weaker financial performance likely weighing on stock price and investor sentiment.
CytomX Therapeutics reported Q2 2026 financial results and issued a business update. Quarterly financial results and strategy updates typically produce moderate effects on valuation and sentiment.
5 Jun
Regeneron expanded its partnership with CytomX Therapeutics. Positive Lynozyfic trial results were reported, triggering a valuation review of Regeneron. Expanded Regeneron partnership significantly strengthens CytomX pipeline funding and strategic positioning.
4 Jun
REGN expands cancer deal with CytomX for bispecific therapeutics. Expanded REGN partnership advances CTMX bispecific cancer pipeline and strengthens strategic positioning.
3 Jun
CytomX expands strategic research collaboration with Regeneron to develop conditional bispecific therapeutics for cancer treatment. Expanded Regeneron collaboration advances CytomX pipeline and partnership strategy in bispecific cancer therapeutics.
2 Jun
CytomX Therapeutics held Q4 2025 earnings call covering financial results, pipeline updates and corporate outlook. Quarterly earnings calls disclose results and guidance that can move stock price and sentiment in the near term.
28 May
New colorectal cancer data is shifting CytomX Therapeutics' development outlook while highlighting added clinical and regulatory risks for its pipeline. New colorectal cancer data can materially alter CTMX pipeline trajectory and investor sentiment.
11 May
CytomX Therapeutics, Inc. (NASDAQ:CTMX) beat analyst earnings forecasts, prompting analysts to raise their price targets and future forecasts. Earnings beat and upward analyst revisions indicate strong financial momentum likely to boost investor sentiment and stock performance.
8 May
CytomX Therapeutics (CTMX) released Q1 2026 earnings call transcript detailing financial results, pipeline updates, and forward guidance. Q1 2026 earnings transcript discloses quarterly financials, clinical progress, and strategic outlook significantly influencing CTMX investor sentiment and stock trajectory.
CytomX Therapeutics held its Q1 2026 earnings call covering quarterly financial results, operational updates, and forward guidance. Quarterly earnings call delivers financial metrics and outlook that can shift near-term investor sentiment and valuation.
7 May
CytomX Therapeutics reported Q1 earnings highlights including financial results, clinical pipeline updates on PROBODY therapeutics, partnership progress with Amgen and Bristol Myers Squibb, and reaffirmed 2024 guidance. Q1 earnings highlights provide moderate updates on financials, pipeline advancements, and guidance that may influence investor sentiment without transformative changes.
CytomX Therapeutics announced Q1 2026 financial results and provided a business update. Quarterly financial results and business updates moderately influence financial performance and investor sentiment.
14 Apr
CytomX Therapeutics, Inc. (CTMX) stands out as a top healthcare penny stock due to promising progress in colorectal cancer treatment developments. Colorectal cancer treatment progress highlights CTMX's potential in oncology, likely driving significant investor sentiment and stock trajectory shifts.
12 Apr
Analysts turn bullish on CytomX Therapeutics (CTMX) after the company prices a $250 million offering. A $250 million offering provides major capital infusion to fuel CTMX's clinical pipeline and drives positive analyst sentiment.
10 Apr
New colorectal cancer data shifts the narrative for CytomX Therapeutics (CTMX), highlighting potential advancements in their oncology pipeline. New colorectal cancer data signals major strategic developments capable of significantly impacting CTMX's competitive position and investor sentiment.
6 Apr
CytomX Therapeutics (CTMX) advances key treatment for metastatic colorectal cancer. Progress on key metastatic colorectal cancer treatment strengthens CTMX's oncology pipeline and could significantly boost market performance.
27 Mar
CytomX Therapeutics (CTMX) gains analyst confidence due to positive progress in clinical trials. Trial progress driving analyst confidence suggests moderately noticeable positive influence on CTMX's market sentiment and performance.
26 Mar
New colorectal cancer data shifts the narrative for CytomX Therapeutics (CTMX), highlighting potential advancements in their oncology pipeline. New colorectal cancer data signals a major shift in CTMX's oncology strategy and investor outlook.
20 Mar
CytomX Therapeutics (CTMX) valuation reviewed after positive Phase 1 expansion results for Varsetatug Masetecan, highlighting promising early safety and efficacy data in oncology. Positive Phase 1 expansion results for Varsetatug Masetecan represent a significant clinical milestone that could enhance CTMX's pipeline prospects and drive substantial investor interest.
17 Mar
CytomX Therapeutics priced a $250 million underwritten public offering of common stock and pre-funded warrants. $250 million capital raise significantly strengthens financial runway for clinical programs and operations.
CytomX Therapeutics (CTMX) stock rallied sharply after strong Phase I study data showed promising efficacy and safety for its investigational colorectal cancer therapy. Strong Phase I data in colorectal cancer boosts CTMX's oncology pipeline validation, driving stock rally and potential for accelerated development or partnerships.
16 Mar
CytomX Therapeutics (CTMX) stock surged on March 16 following positive Phase 1 colorectal cancer trial data. Positive Phase 1 colorectal cancer data triggered a stock surge, indicating significant investor enthusiasm for early clinical progress.
CytomX Therapeutics (CTMX) Q4 2025 earnings call highlights promising Phase 1 data and other developments. Promising Phase 1 data advances CytomX's pipeline and could significantly enhance investor sentiment and stock trajectory.
CytomX Therapeutics (CTMX) shares surged on positive clinical data for its masked antibody-drug conjugate (ADC) in colorectal cancer. Positive data from masked ADC in colorectal cancer validates CytomX's core PROBODY platform, driving stock surge and enhancing pipeline prospects.
CytomX Therapeutics released Q4 earnings snapshot detailing financial results for the quarter. Q4 earnings snapshot provides critical financial metrics that significantly influence investor sentiment and stock trajectory.
CytomX Therapeutics reported Q4 earnings call highlights, covering financial results, clinical pipeline updates including PROBODY progress, partnership developments, and 2024 guidance. Q4 earnings highlights detail financials, pipeline advancements, and outlook, moderately affecting investor sentiment and near-term performance.
CytomX Therapeutics (CTMX) reported a Q4 net loss and missed revenue estimates. Q4 loss and revenue miss moderately affect financial performance and investor sentiment.